Literature DB >> 7964223

Infection in systemic lupus erythematosus.

S Janwityanuchit1, K Totemchokchyakarn, K Krachangwongchai, M Vatanasuk.   

Abstract

A review of 1,069 total admissions of 537 systemic lupus erythematosus (SLE) patients during a 10-yr period at Ramathibodi Hospital showed that 220 episodes which occurred in 137 patients (25.5%) were motivated by infection. Skin was the most common site (23%) with Herpes zoster being the most common organism (15.5%) found in our lupus patients. However, if we considered only major infections, pulmonary tuberculosis, salmonella septicemia and urinary tract infection by E. coli would be the most frequent complications respectively. In the absence of immunosuppressive therapy, infections coincided with the initial manifestation of SLE in 25 patients and were associated with exacerbation of the disease in 20 patients. Mean SLEDAI score in these patients was 8.8, suggesting that active lupus link together with infection. Steroid therapy influenced the rate of opportunistic infections (p = 0.006). Infections were determined to be the cause of death in 23 of 77 patients (29.9%). Opportunistic pathogens played an equal role as other common bacterial organisms in these fatal cases. SLE patients who died from infections were treated with cyclophosphamide in higher proportion than those with no infectious complication (p = 0.025). Our study demonstrated the rate, nature and predisposing factors of infection in SLE which may lead to better anticipation and diminution of morbidity and mortality related to infection in hospitalized patients with SLE.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7964223

Source DB:  PubMed          Journal:  J Med Assoc Thai        ISSN: 0125-2208


  11 in total

1.  Prophylactic use of antibiotics and immunisations in patients with SLE.

Authors:  W R Gilliland; G C Tsokos
Journal:  Ann Rheum Dis       Date:  2002-03       Impact factor: 19.103

Review 2.  Infection-related morbidity and mortality in patients with connective tissue diseases: a systematic review.

Authors:  Matthew E Falagas; Katerina G Manta; Gregoria I Betsi; Georgios Pappas
Journal:  Clin Rheumatol       Date:  2006-12-21       Impact factor: 2.980

Review 3.  Early environmental factors and rheumatoid arthritis.

Authors:  C J Edwards; C Cooper
Journal:  Clin Exp Immunol       Date:  2006-01       Impact factor: 4.330

4.  Infection in children with lupus nephritis receiving pulse and oral cyclophosphamide therapy.

Authors:  Sauwalak Opastirakul; Wattana Chartapisak
Journal:  Pediatr Nephrol       Date:  2005-08-24       Impact factor: 3.714

5.  Burden of Serious Infections in Adults With Systemic Lupus Erythematosus: A National Population-Based Study, 1996-2011.

Authors:  Maria G Tektonidou; Zhong Wang; Abhijit Dasgupta; Michael M Ward
Journal:  Arthritis Care Res (Hoboken)       Date:  2015-08       Impact factor: 4.794

Review 6.  Vaccination of patients with autoimmune inflammatory rheumatic diseases.

Authors:  Johanna Westra; Christien Rondaan; Sander van Assen; Marc Bijl
Journal:  Nat Rev Rheumatol       Date:  2014-12-09       Impact factor: 20.543

7.  Fatal infection in children with lupus nephritis treated with intravenous cyclophosphamide.

Authors:  Kamolwish Laoprasopwattana; Pornsak Dissaneewate; Prayong Vachvanichsanong
Journal:  Pediatr Nephrol       Date:  2009-03-12       Impact factor: 3.714

Review 8.  An insight into rheumatology in Thailand.

Authors:  Worawit Louthrenoo
Journal:  Nat Rev Rheumatol       Date:  2014-09-09       Impact factor: 20.543

9.  Urinary tract infections and lupus erythematosus.

Authors:  C Hidalgo-Tenorio; J Jiménez-Alonso; J de Dios Luna; M Tallada; A Martínez-Brocal; J Mario Sabio
Journal:  Ann Rheum Dis       Date:  2004-04       Impact factor: 19.103

10.  A Prospective Study of Cytomegalovirus-Specific Cell-Mediated Immune Monitoring and Cytomegalovirus Infection in Patients With Active Systemic Lupus Erythematosus Receiving Immunosuppressants.

Authors:  Jackrapong Bruminhent; Suphanan Autto; Porpon Rotjanapan; Pintip Ngarmjanyaporn; Asalaysa Bushyakanist; Suppachok Kirdlarp; Pichaya O-Charoen; Chavachol Setthaudom; Prapaporn Pisitkun
Journal:  Open Forum Infect Dis       Date:  2021-05-16       Impact factor: 3.835

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.